

**Chart 1
Key ADAP Highlights**

State	Financial Eligibility as % of FPL	Medical Eligibility (CD4=CD4 Cell Count, VL=Viral Load)	Total Number of Drugs on Formulary	Nucleoside Reverse Transcriptase Inhibitors (12 Drugs Approved)	Protease Inhibitors Covered (9 Drugs Approved)*	Non-nucleosides Covered (3 Drugs Approved)	Fusion Inhibitors Covered (1 Drug Approved)	"A1" OI Medications (29 PHS Recommended Drugs)	Other Medications Covered	Total FY 2005 Est. Budget (Federal/State Sources)	State Contribution	State \$ Contribution as % of Total Budget	ADAP Clients Served In June 2005	June 2005 Per Capita Drug Expend.	Cost-Containment Measures in Place as of February 2006
Alabama	250%		38	12	9	3	1	8	5	\$13,305,055	\$2,999,632	23%	915	\$1,091	Waiting list; waiting list for Fuzeon
Alaska	300%		72	12	9	3	0	22	26	\$517,035	\$0	0%	37	\$1,019	Waiting list
American Samoa	NR	NR	NR	NR	NR	NR	NR	NR	NR	\$2,360	NR	NR	NR	NR	
Arizona	300%		91	12	9	3	1	14	52	\$10,326,619	\$1,000,000	10%	918	\$939	
Arkansas	200% (300%)	CD4<350 or VL>55,000	53	12	9	3	1	14	14	\$3,393,643	\$0	0%	272	\$1,252	Waiting list
California	<400%; 400% - \$50,000 - sliding		153	12	8 (9)	3	1	27	102	\$264,291,174	\$84,961,250	32%	18,275	\$1,190	
Colorado	300%		48	12	9	3	1	18	5	\$11,425,978	\$4,413,606	39%	1,045	\$869	
Connecticut	400%		191	12	9	3	1	21	145	\$18,401,556	\$1,776,352	10%	1,205	\$1,185	
Delaware	300%; 301% - 500% - sliding		238	12	9	3	1	23	190	\$3,379,523	\$40	0%	249	\$585	
District of Columbia	400%		78	12	8 (9)	3	1	17	37	\$14,648,361	\$0	0%	726	\$1,015	
Florida	350%		71	12	9	3	1	11	36	\$99,702,484	\$9,000,000	9%	8,682	\$695	
Georgia	300%	CD4≤350 or, if CD4>350, VL≥55,000	56	12	9	3	1	18	13	\$43,205,839	\$11,305,339	26%	4,162	\$902	
Guam	< 200%; ≥ 200% - sliding		19	5	4	2	0	8	0	\$101,695	\$0	0%	5	\$1,677	
Hawaii	400%		95	12	9	3	1(0)	22	48	\$2,668,577	\$440,535	17%	211	\$986	
Idaho	200%		41	11	7(8)	3	0	16	4	\$1,284,073	\$177,500	14%	76	\$1,418	Waiting list
Illinois	400%		86	12	8(9)	3	1	20	45	\$37,926,143	\$10,100,000	27%	3,459	\$1,032	
Indiana	300%		97	12	9	3	1	13	60	\$7,242,843	\$0	0%	62	\$1,185	Waiting list
Iowa	200%		35	11(12)	8(9)	3	1	9	3	\$2,029,657	\$375,000	18%	161	\$664	
Kansas	300%		54	12	9	3	1	12	17	\$3,259,977	\$400,000	12%	315	\$1,553	
Kentucky	300%		48	11(12)	7(9)	3	0	13	14	\$5,559,691	\$180,000	3%	401	\$1,092	Waiting list
Louisiana	200%		26	12	9	3	1	0	1	\$17,442,981	\$0	0%	1,704	\$561	Waiting list for Fuzeon
Maine	300%		39	12	9	3	1	9	5	\$1,062,831	\$60,000	6%	43	\$1,930	
Marshall Islands	NR	NR	NR	NR	NR	NR	NR	NR	NR	\$2,360	NR	NR	NR	NR	
Maryland	500%		114	12	9	3	1	26	63	\$45,289,205	\$0	0%	2,301	\$1,173	
Massachusetts	522% plus \$3,100 per dependent (<\$50,000 net annual income)		open formulary	12	9	3	1	29	open formulary	\$21,604,898	\$4,216,175	20%	2,368	\$248	
Michigan	450%		194	12	9	3	1	23	146	\$15,364,472	\$0	0%	1,337	\$1,189	
Minnesota	300%		130	12	8	3	1	20	87	\$6,080,294	\$1,150,000	19%	726	\$489	
Mississippi	400%		52	12	9	2	1	15	13	\$6,495,703	\$700,000	11%	772	\$899	
Missouri	300%		238	12	9	3	1	18	195	\$13,799,516	\$2,096,000	15%	1,200	\$1,025	Reduced formulary; income eligibility restrictions
Montana	330%		144	12	9	3	1	19	100	\$468,112	\$9,000	2%	49	\$828	Waiting list

Data in parentheses are from the prior report, if states made changes since that time. The 2005 Federal Poverty Level (FPL) was \$9,570 (slightly higher in Alaska and Hawaii) for a household of one. **NR** indicates not reported.
 *Aptivus (tipranavir) was approved in June 2005; therefore, several states added it to their formularies after October 1, 2005, the date of the survey. Given the discontinuation of Fortovase (saquinavir soft-gel), the survey counts Fortovase and Invirase (saquinavir hard-gel) as one drug for the purpose of tabulating the number of protease inhibitors covered on an ADAP's formulary.
 **New Hampshire will only reimburse for non-ARV treatments if a patient is currently receiving ARV therapy.

(continued on next page)

Chart 1
Key ADAP Highlights

State	Financial Eligibility as % of FPL	Medical Eligibility (CD4=CD4 Cell Count, VL=Viral Load)	Total Number of Drugs on Formulary	Nucleoside Reverse Transcriptase Inhibitors (12 Drugs Approved)	Protease Inhibitors Covered (9 Drugs Approved)*	Non-nucleosides Covered (3 Drugs Approved)	Fusion Inhibitors Covered (1 Drug Approved)	"A1" OI Medications (29 PHS Recommended Drugs)	Other Medications Covered	Total FY 2005 Est. Budget (Federal/State Sources)	State Contribution	State \$ Contribution as % of Total Budget	ADAP Clients Served In June 2005	June 2005 Per Capita Drug Expend.	Cost-Containment Measures in Place as of February 2006
Nebraska	200%		104	12	8(9)	3	0	15	66	\$1,474,557	\$150,000	10%	265	\$533	Waiting list
Nevada	400%		69	12	9	3	1	13	31	\$6,996,445	\$1,565,704	22%	704	\$885	
New Hampshire	300%	At least one: CD4<350, or currently on ARV therapy, or currently has a designated OI	open formulary,** Hep C drugs and Fuzeon excluded (open formulary)	12	9	3	0(1)	27	open formulary, Hep C drugs and Fuzeon excluded	\$2,718,924	\$180,000	7%	137	\$1,050	Reduced formulary; medical eligibility restrictions
New Jersey	500%		open formulary	12	9	3	1	29	open formulary	\$64,592,155	\$9,000,000	14%	3,964	\$1,437	
New Mexico	300%		69	12	9	3	1(0)	18	26	\$2,293,895	NR	NR	NR	NR	
New York	460%		480	12	9	3	1	27	428	\$237,916,843	\$37,350,000	16%	12,686	\$1,556	
North Carolina	125%		59	12	9	3	1	16	18	\$30,408,944	\$12,120,856	40%	1,887	\$1,511	
North Dakota	400%		94	12	7(8)	3	0	19	53	\$259,493	\$0	0%	33	\$674	
N. Mariana Islands	100%		open formulary	12	9	3	1	29	open formulary	\$4,720	\$0	0%	6	\$505	
Ohio	500% (<\$46,550 gross annual income)		86	12	9	3	1	15	46	\$16,214,008	\$338,787	2%	1,371	\$240	
Oklahoma	200%		53	12	9	3	1	18	10	\$5,474,149	\$884,032	16%	611	\$770	Annual per capita expenditure limit
Oregon	200%		63	12	9	3	1	22	16	\$7,357,790	\$977,678	13%	1,028	\$265	
Pennsylvania	<\$30,000 gross annual income		76	12	9	3	1	22	29	\$42,485,124	\$13,448,000	32%	3,186	\$1,465	
Puerto Rico	NR (200%)	NR	124	12	8(9)	3	1	23	77	\$31,716,607	\$1,199,828	4%	3,750	\$1,304	
Rhode Island	400%		67	12	9	3	1	15	27	\$2,109,545	NR	NR	NR	NR	
South Carolina	300%, 300% - 550% - sliding (300%)		54	11	8(9)	3	1	14	17	\$15,087,564	\$500,000	3%	1,793	\$753	
South Dakota	300%		44	12	0	3	0	12	17	\$471,692	\$0	0%	59	\$503	Annual per capita expenditure limit
Tennessee	300%		91	12	9	3	1	19	47	\$17,612,899	\$0	0%	346	\$521	Reduced formulary
Texas	200%		41	12	9	3	1	11	5	\$95,072,995	\$30,509,949	32%	8,802	\$816	Waiting list for Fuzeon
Utah	400%		37	10	9	3	1	11	3	\$2,602,257	\$180,000	7%	225	\$845	Reduced formulary; cost sharing
Vermont	200%		92	12	9	3	1	18	49	\$622,594	\$0	0%	136	\$305	
Virgin Islands (U.S.)	200%		38	10	8	3	0	9	8	\$709,945	\$0	0%	57	\$827	
Virginia	300%/333% in Northern VA	CD4≤500 for NRTIs, Pis, and NNRTIs (None)	68	12	9	3	1	23	20	\$19,844,417	\$2,612,200	13%	1,781	\$1,125	
Washington	300%		179	12	9	3	1	21	133	\$16,441,895	\$5,587,602	34%	1,194	\$644	
West Virginia	250%		33	12	8(9)	3	0	6	4	\$2,165,992	\$36,890	2%	183	\$1,001	Waiting list
Wisconsin	300%		69	12	9	3	1	21	23	\$5,334,712	\$464,000	9%	477	\$999	
Wyoming	200%		80	12(11)	9	3	0	17	39	\$737,418	\$367,500	50%	47	\$1,321	

Data in parentheses are from the prior report, if states made changes since that time. The 2005 Federal Poverty Level (FPL) was \$9,570 (slightly higher in Alaska and Hawaii) for a household of one. **NR** indicates not reported.

*Aptivus (tipranavir) was approved in June 2005; therefore, several states added it to their formularies after October 1, 2005, the date of the survey. Given the discontinuation of Fortovase (saquinavir soft-gel), the survey counts Fortovase and Invirase (saquinavir hard-gel) as one drug for the purpose of tabulating the number of protease inhibitors covered on an ADAP's formulary.

**New Hampshire will only reimburse for non-ARV treatments if a patient is currently receiving ARV therapy.